文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

从三药到单一片剂:高治疗经验MDR HIV感染者简化至BIC/FTC/TAF

From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

一项前瞻性观察性研究纳入62例多重耐药HIV感染者,因药物相互作用、依从性差或毒性换用BIC/FTC/TAF。48周无病毒学失败,ITT疗效91%(95%CI 81%-99%),耐受性良好,血脂下降且肾功能稳定。

要点

  • 经治MDR HIV感染者换用BIC/FTC/TAF后48周无病毒学失败。
  • ITT疗效91%,OT疗效94%,5年维持治疗概率91%。
  • 换药后总胆固醇和LDL-C显著下降,肾功能稳定。

核心结论

  • 在高治疗经验且病毒学抑制的MDR HIV感染者中,换用BIC/FTC/TAF耐受性良好并维持病毒学控制。

研究设计与样本

  • 前瞻性观察性研究,纳入62例因药物相互作用、依从性差或毒性换用BIC/FTC/TAF的MDR HIV感染者,采用生存分析评估病毒学失败概率。

主要发现

  • 换药前病毒学抑制中位7.95年(IQR 2.5-9.7),60%对两类、37%对三类抗逆转录病毒耐药,中位cGSS=2,M184V/I突变34例(68%)。
  • 换药主因为药物相互作用(61%);48周无病毒学失败,3例(5%)因轻度神经精神事件提前停药,2例出现短暂可检测HIV RNA(1.8和1.85 log copies/mL)。
  • ITT疗效91%(95%CI 81%-99%),OT疗效94%(95%CI 87%-100%);总胆固醇和LDL-C显著下降,eGFR和肾小管参数稳定。
  • 排除2例进行性肾功能恶化的糖尿病感染者后,随访32.5个月(IQR 14.1-48.5;199人年)无病毒学失败或额外停药;生存分析5年维持BIC/FTC/TAF概率91%。

临床怎么用

  • 对于病毒学抑制的MDR HIV经治感染者,因药物相互作用、依从性或毒性问题可考虑换用BIC/FTC/TAF简化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the maintenance of virological suppression in people living with multidrug resistance (MDR) HIV (PLWH), who simplified to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). METHODS: We conducted a prospective, observational study of 62 PLWH with MDR who switched therapy because of drug-drug interactions (DDIs), non-adherence or toxicity. Survival analysis was used to assess the probability of virological failure (VF). Cumulative genotypic susceptibility score to BIC/FTC/TAF (cGSS; maximum 3 points) was evaluated. RESULTS: Before the switch, PLWH were virologically suppressed for a median of 7.95 years (interquartile range, IQR, 2.5-9.7), 60% and 37% had resistance to two and three classes of antiretrovirals respectively (median cGSS = 2), and the mutation M184V/I was observed in 34 cases (68%). The main reason for switching was DDIs (61%). At Week 48, there were no VFs, three patients (5%) discontinued early due to mild neuropsychiatric events, and two showed transient detectable HIV RNA levels (1.8 and 1.85 log copies/mL). Thus, the efficacy was 91% (95% CI, 81%-99%, intention-to-treat analysis) and 94% (95% CI, 87%-100%, on-treatment). Total cholesterol and LDL cholesterol decreased significantly after the switch, and estimated glomerular filtration rate and tubular parameters remained stabilized. Excluding two diabetic PLWH with progressive renal deterioration, there were no VFs or additional discontinuations for 32.5 months (IQR, 14.1-48.5; follow-up, 199 person-years). By survival analysis, the probability of remaining on BIC/FTC/TAF was 91% at 5 years. CONCLUSIONS: In highly treatment-experienced PLWH harbouring MDR strains, who were virologically suppressed, switching to BIC/FTC/TAF was well tolerated with maintenance of virological control.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Casado JL, Blanco JL, Izuzquiza I, et al. From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV. J Antimicrob Chemother. 2025. PMID: 41041971. doi:10.1093/jac/dkaf357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。